Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SURF...$5.95..."W"Pattern forming here...Broke the $4 range confirmation point and looking for the Resistance Neckline at $18 range...imo...we shall see...
Cathie Wood from ARKG owns 10% and keeps adding shares. of the SURF float Eli Lily holds 8.5% through LLV ventures fund. institutions own 67% of the 40 million shares outstanding
Cash runway through 2023 ($102.5M in cash as of Sept 30th; received $85Million from GSK GlaxoSmithKline in December.
Two strategic partnerships (Novartis & GSK GlaxoSmithKline) validate strong IO drug discovery capabilities.
GSK GlaxoSmithKline Partnership SRF813 cumulative milestones up to $730 million • Tiered royalties on annual net sales (high single-digit to mid-teens %
Novartis Partnership: NZV930
• Upfront payment of $70M, total cumulative milestones up to $525 million • Tiered royalties on annual net sales (high single-digit to mid-teens %)
Cathie Wood ARKG #1 wall street stock picker bought over a million SURF shares in one day a few weeks back she has doubled her position to over 4 million shares in the stock recently Cathie knows something!
Detailed clinical update for both SRF617 & SRF388 to be presented in the first half of 2021.
SRF388 is the ONLY anti IL-27 targeted agent in late Pre clinical development. Shows antimetastatic tumour activity and increased the production of key inflammatory cytokines.
SRF388 is a blockbuster in the making, the Il-27 targeting antibody. There is compelling evidence clinically to understand IL-27s role in tumour types. This is the next one that will get huge partnership deal!! Can’t wait for phase 1 data.
Surf recap:Partnership with Novartis worth $525M (For SRF373)Partnership with GSK GlaxoSmithKline worth $730M (For SRF813) Total = 1.15B just for licence worldwide rights.
SURF has 4 other VERY promising targets. SRF617,SRF388, SRF114,SRF231 More partnership deals to come. undervalued and the chart is bullish 1 year is amazing building & looking for continuation to the upside.